Natco Pharma Limited
NSE: NATCOPHARM · Healthcare · Pharmaceuticals · Market cap ₹15,898 Cr
₹810.45+1.65 (+0.20%)
· Prev close ₹808.80 · Volume 31.04 L · 52W ₹774–1,227
NSE: NATCOPHARM · Healthcare · Pharmaceuticals · Market cap ₹15,898 Cr
· Prev close ₹808.80 · Volume 31.04 L · 52W ₹774–1,227
If profit compounds at 40.0% (CAGR) and the stock ends at 25×, buying at ₹810 returns about 49.8% CAGR over 10 years.
| Growth assumption | Profit growth (CAGR) | Return, 10Y CAGR |
|---|---|---|
| Yours | 40.0% | 49.8% |
| Delivered FY22–26 | 70.0% | 81.9% |
| Net profit, last 4 quarters vs the 4 before | −46.1% | −42.3% |
| Half the delivered pace | 35.0% | 44.5% |
Delivered FY22–26 CAGR 70.0%
This is an exit-multiple calculation, not a discounted cash flow. Inputs: EPS for the 4 quarters Sep 2025 to Jun 2026 ₹63.89, price ₹810.45 (13 Nov close). Formula: return = (EPS × exit P/E ÷ price)^(1/10) × (1 + growth) − 1. Net profit growth is applied to EPS, so the share count is held constant. A profit fall of 100% or more has no rate and is left blank. Dividends ignored. Arithmetic, not a forecast.